Project description:This SuperSeries is composed of the following subset Series: GSE18486: CDK inhibitors PHA-848125 and PHA-690509 profiling on A2780 GSE18498: CDK inhibitor PHA-793887 profiling on A2780 GSE18501: CDK inhibitor PHA-848125 gene expression profiling on MCF7 cell line GSE18504: Flavopiridol profiling on A2780 GSE19638: Compounds profiling on MCF7 Refer to individual Series
Project description:The effects of the CDK inhibitor PHA-793887 on the A2780 human adenocarcinoma ovary cell line were analysed by gene expression profiling. The A2780 cell line was treated with PHA-793887 (CDK-887) for 6 hours at a dose equal to 5 time the IC50. Untreated A2780 cells were used as a control. Two replicates per treatment.
Project description:The effects of the CDK inhibitor PHA-793887 on the A2780 human adenocarcinoma ovary cell line were analysed by gene expression profiling.
Project description:The effects of the CDK inhibitors PHA-848125 and PHA-690509 on the A2780 cell line were analysed by gene expression profiling. The A2780 cell line was treated with PHA-848125 (CDk-125) or PHA-690509 (CDk-509) for 6 hours at a dose equal to 5 times the IC50. Untreated A2780 cells were used as a control. Three replicates per treatment.
Project description:The effects of the CDK inhibitor PHA-848125 (referred to as CDK-125) on the MCF7 human adenocarcinoma mammary cell line were analysed by gene expression profiling.
Project description:The effects of the CDK inhibitor Flavopiridol on the A2780 human adenocarcinoma ovary cell line were analysed by gene expression profiling.
Project description:The effects of the CDK inhibitor Flavopiridol on the A2780 human adenocarcinoma ovary cell line were analysed by gene expression profiling. A2780 cells were treated with Flavopiridol for 6 hours at a dose equal to 5 times the IC50. Untreated A2780 cells were used as a control. Two replicates per treatment.
